1.
Reversal of the Target Specific Oral Anticoagulants: A Practical Approach to a Situation With Incomplete Information
by Gage, Thomas
American journal of clinical pathology, 2014, Vol.142 (suppl_1), p.A009-A009
2.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
by Ruff, Christian T, Dr
The Lancet (British edition), 2014, Vol.383 (9921), p.955-962
3.
Stroke prevention in atrial fibrillation
by Freedman, Ben, Prof
The Lancet (British edition), 2016, Vol.388 (10046), p.806-817
4.
Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report
by Lip, Gregory Y H
Chest, 2018, Vol.154 (5), p.1121-1201
5.
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of...
by Wallentin, Lars, Prof
The Lancet (British edition), 2010, Vol.376 (9745), p.975-983
6.
The use of anticoagulants in the management of atrial fibrillation among general practices in England
by Cowan, Campbell
Heart (British Cardiac Society), 2013, Vol.99 (16), p.1166-1172
7.
Deep vein thrombosis and pulmonary embolism
by Di Nisio, Marcello, Dr
The Lancet (British edition), 2016, Vol.388 (10063), p.3060-3073
8.
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants ( Dabigatran , Rivaroxaban , Apixaban ) Versus Warfarin in Patients With Atrial Fibrillation
by Miller, Corey S., BA
The American journal of cardiology, 2012, Vol.110 (3), p.453-460
9.
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
by Mega, Jessica L, Dr
The Lancet (British edition), 2015, Vol.385 (9984), p.2280-2287
10.
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data
by Heneghan, Carl, Dr
The Lancet (British edition), 2012, Vol.379 (9813), p.322-334
11.
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants
by Halvorsen, Sigrun
European heart journal. Cardiovascular pharmacotherapy, 2017, Vol.3 (1), p.28-36
12.
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer
by Farge, Dominique, Prof
The lancet oncology, 2016, Vol.17 (10), p.e452-e466
13.
Drug and dietary interactions of warfarin and novel oral anticoagulants: an update
by Nutescu, Edith
Journal of thrombosis and thrombolysis, 2011, Vol.31 (3), p.326-343
14.
Effectiveness and Safety of Non–vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses
by Almutairi, Abdulaali R
Clinical therapeutics, 2017, Vol.39 (7), p.1456-1478.e36
15.
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study
by Perera, Minoli A, PharmD
The Lancet (British edition), 2013, Vol.382 (9894), p.790-796
16.
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
by Hijazi, Ziad, Dr
The Lancet (British edition), 2016, Vol.387 (10035), p.2302-2311
17.
Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial
by Goette, Andreas, Prof
The Lancet (British edition), 2016, Vol.388 (10055), p.1995-2003
18.
Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs
by Pannach, Sven
Journal of gastroenterology, 2017, Vol.52 (12), p.1211-1220
19.
The risk of delayed intracranial hemorrhage with direct acting oral anticoagulants after trauma: A two-center study
by Barmparas, Galinos
The American journal of surgery, 2019, Vol.217 (6), p.1051-1054
20.
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabI...
by Van de Werf, Frans, MD
The American heart journal, 2012, Vol.163 (6), p.931-937.e1
